Genome sequencing for nonsmall-cell lung cancer identifies a basis for nintedanib sensitivity.

1. Martinalbo J, Bowen D, Camarero J et al. Early market access of cancer drugs in the EU. Ann Oncol 2016; 27: 96–105. 2. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013; 14: 1165––1174. 3. Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Oncol 2015; 1: 539–540. 4. Grothey A, Van Cutsem E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303–312. 5. Goldstein DA, Ahmad BB, Chen Q et al. Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer. J Clin Oncol 2015; 33: 3727–3732. 6. American Society of Clinical Oncology. Potential approaches to sustainable, longlasting payment reform in oncology. J Oncol Pract 2014; 10: 254–258. 7. Altman DG, Anderesen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999; 319: 1492–1495. 8. Li J, Qin S, Xu R et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015; 16: 619–629. 9. Yan Y, Grothey A. Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. Onco Targets Ther 2015; 8: 2949–2957. 10. Light DW, Kantarjian H. Market spiral pricing of cancer drugs. Cancer 2013; 119: 3900–3902.